ANNA HOUSMAN: Open Payments
NPI 1609161694 · BRISTOL, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,861 in 71 payments from 19 companies in 2025. Trend: 2023 $1,221 · 2024 $1,619 · 2025 $1,861
Food & beverage: $1,861
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 8 | $429 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $200 |
| Ardelyx, Inc. | 10 | $198 |
| Aimmune Therapeutics, Inc. | 6 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $169 |
| ABBVIE INC. | 7 | $141 |
| Lilly USA, LLC | 3 | $76 |
| Intercept Pharmaceuticals, Inc. | 3 | $71 |
| GENZYME CORPORATION | 2 | $53 |
| Phathom Pharmaceuticals, Inc. | 4 | $51 |
Products named: REZDIFFRA, IBSRELA, ZENPEP, XIFAXAN, ENTYVIO, OMVOH, OCALIVA, RINVOQ.
Industry payments across CT — which companies pay providers there.
